Nucleoside Metabolic Inhibitor [EPC]

190958 reported adverse events

Drugs of this class: FLUOROURACIL DECITABINE CAPECITABINE AZACITIDINE CLOFARABINE CYTARABINE TRIFLURIDINE (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE GEMCITABINE NELARABINE

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

# Side effect Count
0 DIARRHOEA 17749
1 DEATH 14265
2 NAUSEA 12944
3 NEUTROPENIA 10386
4 VOMITING 10306
5 FEBRILE NEUTROPENIA 10091
6 DISEASE PROGRESSION 9381
7 FATIGUE 9301
8 PYREXIA 9079
9 THROMBOCYTOPENIA 7743
See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY 143 0.8667
1 ACUTE MYELOID LEUKAEMIA RECURRENT 444 0.4336
2 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 140 0.4094
3 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 5917 0.3705
4 CAECITIS 166 0.3689
5 MYELODYSPLASTIC SYNDROME TRANSFORMATION 178 0.3655
6 MYCOBACTERIUM CHELONAE INFECTION 148 0.3210
7 NEUTROPENIC COLITIS 355 0.3156
8 TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA 115 0.3059
9 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 273 0.2920
See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]